We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Collaboration to Develop Diagnostic Products

By Labmedica staff writers
Posted on 29 Jun 2005
Print article
Under a recently announced agreement, Biosite (San Diego, CA, USA) has received a license to develop and commercialize immunoassay-based diagnostic products using novel biomarkers discovered by Compugen Ltd. (Tel Aviv, Israel). Using its genomic platform and other proprietary computational tools, Compugen is expected to provide Biosite with comprehensive data on several gene targets to be nominated by BioSite.

Under the terms of the agreement, Compugen gives Biosite an exclusive license to use the selected Compugen targets for immunoassay-based diagnostic applications. In return, Compugen is to receive milestone payments and royalties from the sales of each diagnostic product emerging from the alliance. Compugen retains the exclusive right to pursue further development in the therapeutic field, and Biosite will be entitled to receive from Compugen any milestone payments and royalties arising from a successful therapeutic application.

This collaboration combines Biosite's expertise in rapid, high-affinity antibody development and commercialization of proprietary testing platforms, consisting of both individual diagnostic markers and panels of markers, with Compugen's discovery capabilities. This discovery process relies on the comprehensive predictive analysis of the human proteome provided by the company's genomic platform. The result of this analysis is utilized with various discovery engines, each designed to identify novel proteins with specific characteristics from the vast numbers predicted by the discovery process.

"We hope that this partnership will enable access to novel markers in areas of strategic focus to Biosite that will lead to new product opportunities for us,” stated Gunars Valkirs, Ph.D., senior vice president, discovery, at BioSite.

"We are excited about the opportunity to collaborate with BioSite, a leading provider of rapid diagnostic products and antibody-development technologies,” said Mor Amitai, president and CEO of Compugen.





Related Links:
Compugen
BioSite
Gold Member
Turnkey Packaging Solution
HLX
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
FLU/RSV Test
Humasis FLU/RSV Combo
New
Histamine ELISA
Histamine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.